Navigation Links
1 in 10 children using cough, cold medications
Date:5/3/2008

Boston, MAResearchers from Boston Universitys Slone Epidemiology Center have found that approximately one in ten U.S. children uses one or more cough and cold medications during a given week. These findings will be presented today at the 2008 Pediatric Academic Societies & Asian Society for Pediatric Research Joint Meeting in Honolulu, Hawaii.

Pediatric cough and cold medications are widely marketed in the U.S. but surprisingly little is known about just how often they are used in children. This information is especially important in light of recent revelations that cough and cold medications are responsible for serious adverse events and even deaths among children.

To define the frequency and patterns of use, the researchers analyzed data between 1999 and 2006 from the Slone Survey, a national telephone survey of medication use in a representative sample of the U.S. population. The authors considered all oral medicines that are approved by the FDA to treat childrens coughs and colds.

The researchers found that in a given week, at least one cough and cold medication was used by 10.1 percent of U.S. children. In terms of active ingredients contained in these medications, exposure was highest to decongestants and antihistamines (6.3 percent each), followed by anti-cough ingredients (4.1 percent) and expectorants (1.5 percent).

Exposures to cough and cold medications was highest among 2 to 5 year olds, but was also high among children under 2 years of age.

Among all the products used, 64.2 percent contained more than one active ingredient. The most commonly used product types were single-ingredient antihistamines, antihistamine/decongestant combinations and antihistamine/decongestant/anti-cough combinations. The researchers also found the use of cough and cold medications declined from 12.3 percent in 1999-2000 to 8.4 percent in 2005-2006.

According to the researchers the especially common use of cough
'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8491
Boston University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Children of depressed moms do better when dad is involved, SLU researcher finds
2. High pollution linked to poor lung function growth in children in Mexico City
3. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
4. Obese Children Miss More School Days
5. Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Practice-based intervention has sustained benefits for children and families
10. 1.5 million children could be saved
11. Annual flu shot cuts need for doctors visits, hospitalization among children
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Skincare Industry Newcomer Shines 51058 1Skincare Industry Newcomer Shines 51058 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call 51052 1